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The ‘injury hypothesis’ in organ transplantation suggests that
ischemia–reperfusion injury is involved in the adaptative
alloimmune response. We previously found that a strong
immune/inflammatory response was induced by ischemia
during kidney transplantation in rats. We show here that
immature dendritic cells (DCs) undergo hypoxia-mediated
differentiation comparable to allogeneic stimulation.
Hypoxia-differentiated DCs overexpress hypoxia inducible
factor-1a (HIF-1a) and its downstream target genes, such as
vascular endothelial growth factor or glucose transporter-1.
Rapamycin attenuated DC differentiation, HIF-1a expression,
and its target gene expression in a dose-dependent manner
along with downregulated interleukin-10 secretion.
Coculture of hypoxia-differentiated DCs with CD3
lymphocytes induced proliferation of lymphocytes, a process
also neutralized by rapamycin. Furthermore, in vivo
examination of ischemia–reperfusion-injured mouse kidneys
showed a clear maturation of resident DCs that was blunted
by rapamycin pretreatment. Our results suggest that hypoxia
is a central part of the ‘injury hypothesis’ triggering DC
differentiation under hypoxic conditions. Rapamycin
attenuates the hypoxic immune-inflammatory response
through inhibition of the HIF-1a pathway.
Kidney International (2008) 73, 816–825; doi:10.1038/sj.ki.5002792;
published online 23 January 2008
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During recent years, dendritic cells (DCs) attracted much
interest in the medical community due to their strategic role
in immune response linking innate and acquired immune
responses and in the induction of tolerance to self antigens.
In the transplant setting, immune-mediated injury is not
only caused by alloimmune response, but also, as referred by
the ‘injury hypothesis,’ as a result of other factors that may
play an important role (for example, ischemia–reperfusion
injury (IRI)).1–3 IRI has been shown to activate innate
immunity in rat kidneys4 and clinical data have invariably
confirmed that there is a link between delayed graft function
and a higher rate of acute rejection.5 In an experimental
transplant model, our group found that ischemia added to
the allogeneic background resulted in significant inflamma-
tory injury, clearly activating and accelerating the cellular
mechanisms involved in this process.3 Several reports even
corroborate that the immune response vis-a`-vis hypoxia can
occur in native kidneys, implicating T cells as the main
effectors.6 Moreover, a relationship between upregulation of
DC differentiation and ischemic acute renal failure has
recently been described.7 In the reperfusion phase in rats
(peripheral blood monocytes) suffering from ischemic acute
renal failure, there was an increase in the number of DCs
differentiated from PBMo, and higher expression of MHC
class II, IFN-g, and interleukin (IL)-12 in DCs.7 Thus, there is
a growing evidence of the pivotal role of the different steps of
immune system in the pathophysiology of IRI, not only
concerning T cells.
In association to this, many immunosuppressive agents
have been studied so as to interfere with differentiation
toward mature DCs. Rapamycin, a macrolide drug used
in clinical transplantation by its antiproliferative effects on
T lymphocytes, has been shown to reduce antigen uptake
by immature DCs (iDCs) and to decrease expression of
costimulatory molecules on mature DCs in a dose-dependent
way.6 Rapamycin is also known to reduce proliferative
responses to hypoxia in many cell lines.8,9 Our group
previously demonstrated in a rat kidney transplant model
that rapamycin regimens prevent immunogenicity derived
from early postischemic inflammatory responses.2
Thus, in this study, we had two objectives: first, to assess
whether in vitro exposure to hypoxia triggers iDCs to
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undergo differentiation and if rapamycin can mitigate this
cell process, thus attenuating the activation of immune
response; and second, to evaluate IRI effect in resident DC
(rDC) maturation in an in vivo model of rodents treated or
not with rapamycin.
RESULTS
Phenotype switch of DCs following lymphocyte or hypoxia
exposure
In this study, we made use of CD11cþ -CD14þ human
monocytes, exposing them to granulocyte–macrophage
colony-stimulating factor (GM-CSF) and IL-4 (with or
without rapamycin), and then subsequently cocultured with
lymphocytes on day 6, when their phenotype was compatible
with iDCs (CD14) (data not shown). DC differentiation was
monitored at day 7 by flow cytometry using anticostimula-
tory molecule (anti-CD40/anti-CD80/CD86), myeloid DC
molecule (anti-CD11c), and mature phenotype molecule
(anti-CD54/anti-CD58/anti-HLADR) staining. A low popu-
lation of CD14 cells, and CD11cþ not previously exposed
to any other agonist, became CD40 positive at day 7, which
indicates that DCs remain immature under control condi-
tions (Figure 1a). By contrast, iDCs exposed to allogeneic or
isogeneic lymphocytes showed high expression of CD40 and
the other surface molecules (Figure 1b), which is consistent
with DC differentiation. We then examined the forward/side
scatter, quantified by mature DC phenotype surface molecule
staining, which was characterized by a higher cell surface than
immature forms. Allogeneic stimulation revealed higher
numbers of mature cells (57.3%) compared to stimulation
with isogeneic lymphocytes, resulting in a differentiation rate
of 37.1%, while nonstimulated cells remained poorly
differentiated (6.3%) (mean values for three experiments)
(Po0.05). DC differentiation by isogeneic stimulation is a
characteristic feature of DCs but not macrophages.
Immature DCs exposed for 48 h to hypoxia (0.5% oxygen)
at day 5 showed clear CD40 and all the other surface markers
(Figure 2) overexpression at day 7 (Po0.05). Maturation
changes were also observed in the forward/side scatter analysis,
amounting to 54.8% (mean value for six experiments) of
mature DCs. Time kinetics performed for 12, 24, 48, and 72 h
revealed the most prominent changes in iDC differentiation
occurring at 48 h, with no differences over prolonged
incubation periods (data not shown). The combination of
allogenic DC stimulation performed under hypoxia showed no
additive response with regard to the phenotype switch.
To further analyze DC differentiation under hypoxia
stimulus, we evaluated succinimidyl ester of carboxyfluore-
scein diacetate (CFSE) staining. The increase in gate R1 of
mature forms (CD40þ /CD11cþ /CD56þ ) under hypoxia
was associated to a similar amount of DNA synthesis than the
low population of CD40þ /CD11cþ /CD56þ DCs in gate R1
of cells not exposed to stimuli (control conditions) (data not
shown). So, hypoxia does not contribute to an increase in
CD40þ /CD11cþ /CD56þ DC proliferation, but induces iDC
differentiation.
Rapamycin decreased DC differentiation expression in
response to hypoxia
Rapamycin was used in further experiments to evaluate
mTOR involvement on DC differentiation under hypoxia.
This macrolide was added in a dose-dependent manner, with
hypoxia-induced differentiation followed by forward/side
scatter analysis and quantification by CD40 and the other
maturation markers expression. Rapamycin (at a dose of
0.1 nM) significantly reduced DC maturation to 33.2%
(mean), while 10 nM rapamycin reduced differentiation to
control values (Figures 3 and 4).
At the same time, we monitored DiOC6 and Annexin-V
staining to exclude any interference by apoptosis, thereby
accounting for the inhibitory effect of rapamycin. Results
showed that there was no increase in apoptosis either in
CD14þ cells or in mature DCs exposed to rapamycin (data
not shown).
DC cytokine secretion under hypoxia and allogenicity: effect
of rapamycin
Interleukin-2, -4, -6, -10, TNF-a, and IFN-g protein secretion
was quantitatively measured following cell stimulation by the
cytometric bead array (CBA) system. Under hypoxia, only
the levels of IL-10 and IFN-g significantly got increased
(Figure 5). Interestingly, the increase in IL-10 secretion was
40% higher than the increase in IFN-g production (ratio
of coefficient of variation of cytokine increase 0.45/0.32).
iDCs under hypoxia and exposed to rapamycin showed a
significant reduction in IL-10 secretion and a nonsignificant
increase in IFN-g. In contrast, IFN-g was oversecreted under
allogeneic exposure and IL-4 under isogeneic exposure, while
rapamycin produced an increase of IL-6 when added to
allogeneic coculture.
HIF-1a pathway alterations in hypoxia-differentiated DCs
In the following experiments, it was our intention to monitor
expression of vascular endothelial growth factor (VEGF)
and glucose transporter-1 (Glut-1) by quantitative reverse
transcription-PCR in association with the differentiation
induced by hypoxia. VEGF and Glut-1 are considered
classical hypoxia inducible factor-1a (HIF-1a) target genes
and therefore are indicative of hypoxic responses. As shown
in Figure 6a, both VEGF and Glut-1 expression are hypoxia
inducible. Glut-1 expression was induced 30-fold, whereas
VEGF expression increased roughly 15-fold compared with
normoxic controls.
Taking into account that rapamycin attenuated hypoxia-
DC differentiation, we also determined the impact of
rapamycin on VEGF and Glut-1 expression. In the presence
of 5 nM rapamycin, hypoxia no longer generated a significant
increase in mRNA, either of VEGF or of Glut-1 (Figure 6a).
Thus, our results suggest the presence of an mTOR-
dependent pathway facilitating hypoxia-induced gene ex-
pression.
Further mRNA expression analysis revealed a threefold
increase of HIF-1a mRNA under hypoxia treatment, a
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situation resembling DC differentiation (Figure 6b). Rapa-
mycin at a dose of 5 nM did not interfere and revealed only
insignificant changes on its own. Contrarily to mRNA,
HIF-1a protein is more stable under hypoxia, and its quanti-
fication is more accurate in this situation as the protein is
regulated in a posttranscriptional level. Thus, we monitored
protein expression of HIF-1a by western blot analysis
(Figure 7). Under hypoxic conditions, in which we observed
DC differentiation, we also noted the robust expression of
HIF-1a, compared with its complete absence under norm-
oxia. Interestingly, rapamycin (5 nM) attenuated hypoxia-
evoked HIF-1a expression. At a dose of 10 nM, rapamycin
nearly abrogated hypoxia-evoked HIF-1a expression (data
not shown). Thus, blocking the mTOR pathway affects not
only DC differentiation but also HIF-1a expression.
To further assess HIF-1a involvement in DC maturation
under hypoxia, we exposed iDCs to desferrioxamine, a
chemical inducer of HIF-1a stabilization under normoxia.
Cell supplementation of DFX 100 mM for 3 h on day 5 was
associated with DC differentiation, similarly as hypoxia did
(data not shown).
Functional DC evaluation: CD3 lymphocyte proliferation
study
To evaluate the effect of DCs differentiated under different
conditions on CD3 lymphocyte proliferation, we performed
CFSE/CD3 costaining. Lymphocytes were CFSE stained and
exposed to mature DCs (under hypoxia or allogeneic stimuli)
or exposed to rapamycin-treated hypoxia-DC for 24 h. After
10 days, we analyzed by fluorescence-activated cell sorting
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Figure 1 | iDC maturation and CD40 expression under control, allogeneic and isogeneic conditions. (a) DC maturation and CD40
expression in control iDCs. Monocytes were cultured with IL-4 and GM-CSF for 5 days. On day 7, cells were harvested and CD11cþ cells were
analyzed for CD40 surface marker by flow cytometry. Mean fluorescence intensity of iDCs (not exposed to stimuli for maturation and used as
controls) and morphologic changes (FSC-H and SSC-H) were markedly low. The results are representative of three experiments. Gate R1
represents the percentage of mature forms CD11cþ ; gate R2 cells did not express CD40 and exhibited lower shape and density (immature
forms CD11cþ ); M1 represents positive fluorescence intensity for CD40 staining. (b) Allogeneic and isogeneic conditions cause phenotypic and
morphologic changes in iDCs. Monocytes were cultured with IL-4 and GM-CSF. On day 6, iDCs were cocultured with lymphocytes from other
donors. On day 7, cells were harvested and CD11cþ cells analyzed for CD40 surface marker by flow cytometry. Mean fluorescence intensities of
DCs under allogeneic conditions and morphologic changes (FSC-H and SSC-H) were markedly higher than under control conditions. The results
are representative of three experiments. Isogeneic stimuli also caused phenotypic changes in iDCs.
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(FACS) the CFSE staining of CD3 cells that were not exposed
to DCs (control) and of CD3 cells exposed to DCs. CD3
lymphocyte proliferation was significantly higher after
coculture with hypoxia- or allogeneic-differentiated DCs.
Interestingly, proliferation rate was significantly reduced
when CD3 cells were cocultured with rapamycin-treated
hypoxia-DCs, although those lymphocytes were not directly
treated with rapamycin (Figure 8).
Resident intrarenal DCs undergo maturation following
ischemia–reperfusion injury
To further evaluate hypoxia-DC differentiation, we verified
whether in vivo kidney rDCs differentiate after IRI. To
distinguish rDCs from other intrarenal cell populations, flow
cytometric analysis was performed. Cell suspensions prepared
from the kidney 24 h after ischemia, control kidneys, and
ischemic kidneys from rapamycin-treated mice (8 mg kg1 for
3 days prior to IRI) were stained for the pan-leukocyte marker
CD45 in combination with CD11c, CD80, and either Ly6C
and 7-AAD (to distinguish from recruited monocytes).10
Results of the overall analysis of cell subsets expressed as
percentage of the total CD45 are presented in Figure 9. The
proportion of viable CD80-differentiated DCs (7-AAD/
CD45þ /CD11cþ /Ly6C) remained low in control kidneys.
There was an increase of viable mature rDCs in ischemic
kidneys 24 h after renal artery clipping. Ischemia–reperfusion
(IR) was associated with a rich population of CD80 with
larger cell size (reflected by forward scatter; data not
shown). Thus, rDCs within ischemic kidneys exhibited
a more mature phenotype than nonischemic kidneys.
Furthermore, rapamycin-ischemic kidneys showed a reduc-
tion of viable mature CD80 rDC forms, close to control
kidneys.
DISCUSSION
Ischemia–reperfusion injury in solid organ transplantation
has been shown to contribute to the adaptive immune
response involved in acute rejection (1, 4, and 11). It is well-
known that T cells can be activated by oxygen-free radicals
and cytokines, both associated with ischemia and, thus,
orchestrate the immune inflammatory reaction.4 Using a
Fischer-to-Lewis model of kidney transplant, we recently
assessed the distinct contributions of alloreactivity and cold
ischemia to the onset and progression of chronic allograft
nephropathy. We found that ischemia added to the allogeneic
background resulted in significant inflammatory injury,
clearly activating and accelerating the cellular mechanisms
involved in this process. Introducing modifications to the
immunosuppressive treatment, we showed that regimes
incorporating rapamycin suppressed the inflammatory
T-cell-mediated acute cellular changes associated with renal
ischemic injury, improved long-term outcome, and attenu-
ated chronic allograft nephropathy.3
Dendritic cells have been recently implicated in the
coordination of innate and adaptive immune responses due
to the different stages in their life history.5,7 Also, a
relationship between upregulation of DC differentiation
and ischemic acute renal failure has been described,7 thus
connecting ischemia to adaptive response.1,4,11–13 Never-
theless, the impact of reduced oxygen availability in DC
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Figure 2 | Hypoxic conditions cause phenotypic and morphologic changes in iDCs. CD40 staining. Monocytes were cultured with IL-4
and GM-CSF. On day 5, iDCs were exposed to 48 h of hypoxia (0.5%). Mean fluorescence intensities of DCs and morphologic changes (FSC-H
and SSC-H) were markedly higher than under control conditions and comparable to allogeneic exposure. The results are representative
of six experiments.
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differentiation as well as the responsible pathways implicated
in this process and whether rapamycin may play a direct role
on this effect as we found in our in vivo study need to be
established.
We first evaluated in vitro with DCs, two of the injuries
affecting a graft during transplantation, for example, IR and
alloreactivity. Although ischemia is a complex process in vivo,
hypoxia of cell cultures is accepted as a closed environment to
study IR. Our findings show that iDCs exposed to hypoxia
underwent cell maturation comparable to, and as strong as,
alloantigen-dependent maturation. Paradoxically, the combi-
nation of the hypoxic and allogeneic stimulus revealed no
additive effects. Curiously, iDCs exposed to isogeneic culture
alone showed an increase in costimulatory molecular
expression. Interestingly, it has been reported that DCs but
not macrophages are capable of being activated under
isogeneic mixed cultures.14,15
To verify whether this maturation in DC phenotype under
hypoxia triggers an allostimulatory effect, we analyzed DC
cytokine production and the lymphocyte response under
mixed culture. High IL-10 secretion was revealed on hypoxia-
stimulated DCs. Uniquely among cytokine from hemato-
poietic cells, IL-10 is a pleiotropic molecule that displays
both immunostimulatory and immunoregulatory activities.
Although human DCs are generally poor producers of
IL-10, it has been shown that high IL-10-producing capacity
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Figure 3 | Rapamycin exerts a dose-dependent effect on hypoxia-stimulated iDCs. Monocytes were cultured with IL-4 and GM-CSF
and treated with rapamycin 0.1 nM, 5 nM, and 10 nM. On day 5, iDCs were exposed to 48 h of hypoxia (0.5%). Mean fluorescence intensity of
DCs and morphologic changes (FSC-H and SSC-H) were abrogated in a dose-dependent manner by rapamycin treatment. The results are
representative of three independent experiments and expressed as the mean (±s.d.) percentage of mature DCs. Hypoxia-stimulated iDCs
versus control conditions (no stimuli) (*Po0.05). Rapamycin-treated hypoxia-stimulated cells showed a reduction of mature DC forms
versus hypoxia-iDCs (**Po0.05). Rapa, rapamycin.
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can be induced in monocyte-derived DCs by their pretreat-
ment in early stages of maturation with prostaglandin E2
(PGE2).16 In fact, PGE2 can modulate the activities of
professional DCs by acting on their differentiation and their
ability to secrete cytokines.17 In our results, although there
was an upregulation of IFN-g in hypoxia-stimulated iDCs,
usually related to iDC stage maturative change, the IL-10
overproduction was 40% higher. In fact, PGE2 is associated
with suppression of IFN-g in response to maturation stimuli.
It is well-known that hypoxia is associated with increased
levels of PGE2 in several cell lines, enhancing VEGF
expression and HIF-1 transcriptional activity by activating
the mitogen-activated protein kinase pathway.18 Interestingly,
hypoxia-differentiated DCs provoked a clear proliferation of
CD3 lymphocytes similar to allogeneic-differentiated DC
exposure. These data confirm that hypoxia-DCs have a
functional effect, as they evoke a fully immune response, with
lymphocyte expansion.
Definitively, the hypoxia marker genes VEGF and Glut-1
were overexpressed in iDCs exposed to hypoxia, confirming
that iDCs followed the classical adaptive hypoxic-induced
changes. We also examined HIF-1a, a master regulator
molecule under conditions of reduced oxygen availability and
classically upregulated by PGE2. Although extensively studied
in macrophages,19 there are no reports correlating HIF-1a
expression and target gene induction with DC maturation.
Interestingly, in this study, DC maturation, HIF-1a expres-
sion, and HIF-1 target genes expression are interrelated
based on their sensitivity to rapamycin. For instance, some
studies correlate HIF-1a with cell mediated-inflammation. In
fact, the expression of HIF-1a under various immune-
inflammatory conditions such as Crohn’s disease or rheu-
matoid arthritis has recently been noted.20–22 Studies based
on the selective deletion of the HIF-1a gene in granulocytes
and monocytes have also demonstrated its essential role
in myeloid cell mediated-inflammation.23,24 Our findings in
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Figure 4 | Hypoxic conditions cause phenotypic and morphologic changes in iDCs. Monocytes were cultured with IL-4 and GM-CSF
and treated with rapamycin 0.1 nM, 5 nM, and 10 nM. On day 5, iDCs were exposed to 48 h of hypoxia (0.5%) as described in Materials and
Methods. On day 7, cells were harvested and analyzed for CD40, CD80, CD11c, and HLA DR surface markers by flow cytometry. Mean
fluorescence intensities of DCs and morphologic changes (FSC-H and SSC-H) were presented as percentage of CD11cþ double marked
cells and were markedly higher than under control conditions and comparable to allogeneic exposure. (a–c) Mean fluorescence intensity
of DC surface markers was abrogated in a dose-dependent manner by rapamycin treatment. The results are representative of three
experiments. Hypoxia-stimulated iDCs versus control conditions (no stimuli) (*Po0.05). Rapamycin-treated hypoxia-stimulated cells
showed a reduction of mature DC forms versus hypoxia-iDCs (**Po0.05).
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DCs concur with those data. Thus, activation of iDCs
following hypoxia may trigger a local increase in immuno-
genicity, which would tether and activate T cells to draw
an immune-inflammatory response to the organ. Whether
this response is Th1- or Th2-mediated appears an interesting
aim for further studies. Our results may indicate that, as a
consequence of hypoxia, DC maturation links the innate and
the adaptive immune systems, which was previously mainly
attributed to T cells.1
To further explore the involvement of mTOR pathway in
hypoxia related changes in DC stage, we analyzed the
behavior of hypoxia-maturated DC vis-a`-vis rapamycin.
Hypoxia-stimulated iDCs showed a strong downregulation
in DC maturation in the presence of rapamycin, an effect that
occurred in a dose-dependent manner. Increasing concentra-
tions of rapamycin resulted in the complete inhibition of
costimulatory molecular expression. In this sense, Monti
et al.25 recently reported that rapamycin, but not calcineurin
inhibitors, decreased CD40 expression in differentiated DCs
following antigen challenge, leading to the hypothesis that
rapamycin was nontoxic. Thus far, our findings demonstrate
a critical role of mTOR in the regulation of DC maturation
under hypoxia, also defined by Humar et al.26 in smooth
muscle cell proliferation.
The inhibitory effect of rapamycin on DC maturation
under hypoxia was not associated with a relevant induction
of apoptosis. Some discrepancies do exist regarding apoptotic
phenomena on rapamycin-treated DCs. In fact, rapamycin
has been shown to induce apoptosis in iDCs and CD34-
derived DCs but not in monocytes, which exhibit a higher
apparent sensitivity to the drug after 2–3 days of culture.27,28
Nevertheless apoptosis of DCs might also interrupt the
effective presentation of antigen and contribute to the
prevention of allograft rejection through the efficient
inhibition of DC-induced T-cell proliferation.29
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Figure 6 | VEGF, Glut-1 and HiF-1a expression by hypoxia-
stimulated iDC. (a) VEGF and Glut-1 production by hypoxia-
stimulated iDCs or by nonstimulated iDs (control conditions). iDCs
were incubated on day 5 in the presence or absence of hypoxic
conditions for 48 h. Monocytes were treated (or not) with rapamycin
(5 nM). cDNA expression was analyzed by reverse transcription-PCR.
VEGF and Glut-1 production by hypoxia-stimulated iDCs versus
control conditions (no stimuli) (*Po0.05). VEGF and Glut-1
production by hypoxia-stimulated iDCs treated with rapamycin
versus hypoxia-iDCs (**Po0.05). (b) Hypoxia-mediated accumulation
of HIF-1a expression in rapamycin-treated (nM) DCs. Human iDCs
were incubated in the absence or presence of rapamycin and
stimulated (or not) with hypoxia for 48 h. cDNA expression was
analyzed by reverse transcription-PCR. No changes in HIF-1a mRNA
were found when cells exposed to hypoxia were treated with
rapamycin.
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Rapamycin has been also shown to block the protein
synthesis of HIF-1a and its target genes.30–34 This was
confirmed for DCs in our study, where rapamycin decreased
HIF-1a expression as well as VEGF and Glut-1 target gene
expression. Furthermore and as it was expected, IL-10
secretion was also significantly reduced. In fact, rapamycin
inhibits IL-10 production by interfering with the IL-10 gene
transcription.35 Interestingly, CD3 lymphocyte proliferation
rate was significantly reduced when CD3 cells were
cocultured with rapamycin-treated DCs exposed to hypoxia.
Thus, rapamycin, originally known for its interference with
cell-cycle progression, also interrupts HIF-1a expression and
maturation of DCs under hypoxia and, more important, the
consequent lymphocyte expansion.
Recently, novel evidence shows that rDCs participate in
the secretion of inflammatory mediators that contribute to
early pathophysiological events in the ischemic acutely
injured kidney.10 As a final aim in our studies, we wanted
to confirm in vivo the differentiation of rDCs after IRI. Thus,
kidneys exposed to ischemia showed a clear increase in the
number of viable mature rDCs, different from recruited
monocytes. In agreement with in vitro results, rapamycin
treatment abolished this cell differentiation. As it has been
said,10 rDCs in peritubular epithelial space may respond to
endogenous activators of innate immunity, to instigate
secondary responses in renal epithelial and endothelial cells,
and participate in the recruitment of additional circulating
cells to the kidney.
In conclusion, this study brings a further approach of the
impact of reduced oxygen availability in DCs, thus clarifying
the immune inflammatory changes occurring under this
condition. Furthermore and as far as we know, mTOR,
HIF-1a, and HIF-1 target gene activation are linked for the
first time with DC maturation under hypoxic conditions.
MATERIALS AND METHODS
Materials for in vitro and in vivo study
Medium and supplements were purchased from PAA (Linz, Austria).
GM-CSF, human IL-4, Annexin-V, desferrioxamine, 7-AAD, and
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Figure 8 | Lymphocyte proliferation was increased after mature DC exposure. Lymphocytes were CFSE stained and exposed to
mature DCs (differentiation under hypoxia (hypoxia-DCs) or allogeneic stimuli (allo-DCs)) or exposed to rapamycin-treated DCs exposed to
hypoxia (hypoxia-rapa-DCs) for 24 h. After 10 days, we analyzed by FACS CFSE staining on CD3 cells that were not exposed to DCs (control)
and on CD3 cells exposed to DCs. CD3 cells proliferation was significantly higher when those cells were cocultured with mature DCs
(differentiated with hypoxia and allogeneic stimuli) (*Po0.05). Interestingly, proliferation rate was significantly reduced when CD3 cells
were cocultured with rapamycin treated DC exposed to hypoxia (**Po0.05). The results are representative of three independent
experiments and expressed as the geo mean (±s.d.).
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Figure 7 | Hypoxia-mediated accumulation of HIF-1a protein
expression in rapamycin-treated (5 nM) DCs. Human iDCs were
incubated in the absence or presence of rapamycin and stimulated
(or not) with hypoxia for 48 h. Whole cell extracts were prepared and
immunoblotting was performed with anti- HIF-1a and b-actin
antibodies as described in Materials and Methods.
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Figure 9 | Ischemia–reperfusion induced rDC maturation. Cell
suspensions prepared from the kidney 24 h after 30 min of ischemia,
control kidneys, and ischemic kidneys from rapamycin-treated mice
(8 mg kg1 for 3 days prior to IRI) were stained for the pan-leukocyte
marker CD45 in combination with CD11c, CD80, and either Ly6C or
7-AAD. Results of the overall analysis of cell subsets in ischemic,
rapamycin-ischemic, and control kidneys are expressed as percentage
of the total CD45 cell suspensions and are representative for a group
of four mice for each condition. rDCs within ischemic kidneys
exhibited a more mature phenotype than nonischemic kidneys
(*Po0.05). Rapamycin-ischemic kidneys showed a reduction of viable
mature CD80 rDC forms (**Po0.05), close to control kidneys.
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rapamycin were ordered from Sigma (Madrid, Spain). A protein
assay kit was purchased from Bio-Rad (Mu¨nchen, Germany). Anti-
human CD3/CD40/CD54/CD58/CD80/CD86/HLA DR/CD11c and
CD14 monoclonal antibody were obtained from BD-Pharmingen
(Barcelona, Spain) as well as anti-mouse CD45-biotin, CD11c-PE,
CD80-FTIC, anti-CD80-fluorescein isothiocyanate isotype control,
and LyC6-fluorescein isothiocyanate monoclonal antibodies; and
Cytometric Bead Array-CBA, CFSE, and DiOC6 were from
Molecular Probes (Madrid, Spain). Nitrocellulose membrane,
enhanced chemiluminescence (ECL) detection system, and horse-
radish peroxidase-labeled anti-mouse or anti-rabbit secondary
antibodies were delivered by Amershan Biosciences (Freiburg,
Germany). Anti-HIF-1a antibodies and Clontech-Advantage RT-
for-PCR kit were purchased from Becton-Dickinson (Heidelberg,
Germany). Primers were ordered from MWG-Biotech (Ebersberg,
Germany). The peqGOLD-RNAPure kit was acquired from Peqlab
(Erlangen, Germany).
Cell culture
Highly enriched monocytes populations (90% CD14þ ) were
obtained from buffy coats of donors through the courtesy of
Saarbru¨cken hospital (Saarbru¨cken, Germany). Monocytes were
obtained by Ficoll–Percoll gradients, purified by adherence, and
cultured for 7 days on 6 cm dishes (1 106 cells per ml) in RPMI
medium supplemented with 2 mM L-glutamine, 100 U ml1 peni-
cillin, 100 mg ml1 streptomycin and 10% fetal calf serum , 5 ng ml1
IL-4 and 100 ng ml1 of GM-CSF, with or without 0.1 nM, 5 nM, or
10 nM of rapamycin being added on day 1. Cells were kept at 37 1C in
a humidified atmosphere with 5% CO2 and propagated according to
the protocol provided by the American Type Culture Collection.
Medium was changed every second day and prior to experiments
with supplements and inhibitors. Lymphocytes were obtained by
Ficoll–Percoll gradients, purified by nonadherence, and frozen for
subsequent experiments based on isogenic or allogenic mixed
culture.
Cell differentiation
Immature DCs were exposed at day 6 of culture for 24 h to
lymphocytes (1:10 ratio) from the same donor for isogeneic
reactions or to lymphocytes (1:10 ratio) from a different donor
for allogeneic reactions. Hypoxic (0.5% oxygen) conditions were
generated at day 5, exposing iDCs for 12, 24, and 48 h. iDCs were
exposed to hypoxia (0.5% O2, 5% CO2) in a hypoxia workstation
incubator (In vivo 400, Ruskin Technology, UK), thus allowing cell
manipulation without O2 pressure changes.
CD3 lymphocytes were isolated after 24 h of coculture with DCs
and proliferation was evaluated by FACS analyze after 10 days of
culture.
Quantification of apoptosis and cell proliferation rate
Apoptosis was measured by Annexin-V and also by the loss of
mitochondrial membrane potential as detected by decreased
emission from the DiOC6. DiOC6 (40 nM) was added 30 min prior
to the end of incubations and the green fluorescence of the dye was
measured by FACS. Results were expressed as the mean values of
DiOC6 staining. Cell proliferation was assessed by CFSE analyze by
FACS.
Cell phenotype and cytokine analysis by flow cytometry
Granulocyte–macrophage colony-stimulating factor- and IL-4-trea-
ted monocytes (1 106 cells per ml) were cultured for 5 days prior
to stimulation. Following cell stimulation, cells were washed
from the culture dish and transferred to FACS tubes. Thereafter,
CD40/CD80/CD86/HLADR/CD54/CD58 and CD11c antibodies
were added and incubations continued for 45 min. All incubations
were carried out at 4 1C. Flow cytometry analysis was performed
using a FACSCalibur flow cytometer (BD Biosciences, Heidelberg,
Germany). CD14 expression was assessed by fluorescein isothiocyanate-
conjugated anti-CD14 antibodies at days 1 and 5 under resting
conditions.
Interleukin-2, -4, -6, -10, TNF-a, and FN-g secretion protein
levels were quantitatively measured following cell stimulation by
Cytometric Bead Array System (BD Biosciences, San Diego, CA,
USA). The geometric mean values of the log fluorescence in samples
were recorded.
RNA extraction, reverse transcription-PCR, and real-time PCR
Total RNA was isolated using the peqGOLD RNAPure kit according
to the manufacturer’s protocol. Reverse transcription of 1 mg RNA
was performed using oligo(dT) primers and MMLV reverse
transcriptase. The cDNA was diluted 1:5 for further PCR. For
quantitative analysis, equal amounts of 100 ng cDNA were subjected
to real-time PCR using the MyiQ Single-Color Real-Time PCR
Detection System with SYBR-Green as fluorescent dye. The primer
sequences used were as follows: human HIF-1a forward: 50-CTC
AAAGTCGGACAGCCTCA-30, reverse: 50-CCCTGCAGTAGGTTT
CTGCT-30; VEGF forward: 50-TACCTCCACCATGCCAAGTG-30,
reverse: 50 AAGATGTCCACCAGGGTCTC-30; Glut-1 forward: TCA
CTGTGCTCCTGGTTCTG-30, reverse 50- CCTGTGCTCCTGAGAG
ATCC-30; and human RPLO forward: 50-TGACGGGGTCACCCACA
CTGTGCCCATCTA-30, and reverse: 50-CTAGAAGCATTTGCGGT
GGACGATGGAGGG-30. For quantification, the expression was
normalized to the internal standard gene RPLO.
Western blot analysis
Hypoxia inducible factor-1a and actin were quantified by western
analysis. Briefly, cells were scraped off, lysed in 150ml buffer A
(50 mM Tris-HCl, 150 mM NaCl, 5 mM EDTA, 0.5% Nonidet-40,
1 mM PMSF, protease inhibitor cocktail, pH 8.0), and sonicated.
Following centrifugation (15 000 g, 15 min), the protein content in
the supernatant was determined, and 100mg protein was added to
the same volume of 2 SDS-polyacrylamide gel electrophoresis
sample buffer (125 mM Tris-HCl, 2% SDS, 10% glycerin, 1 mM DTT,
0.002% bromophenol blue, pH 6.9) and boiled for 5 min. Proteins
were resolved on 7.5 or 10% SDS-polyacrylamide gels and blotted
onto nitrocellulose membranes. Nonspecific binding was blocked
with 5% milk solution in TTBS (50 mM Tris-HCl, 140 mM NaCl,
0.05% Tween 20, pH 7.2) for 1 h. HIF-1a, actin antibodies (1:1000
in 1% milk/TTBS) were added and incubated overnight at 4 1C.
Afterwards, nitrocellulose membranes were washed three times for
5 min each with TTBS. Blots were then incubated with goat anti-
mouse or goat anti-rabbit secondary antibodies conjugated with
peroxidase for 1 h, washed three times for 5 min each with TTBS,
followed by ECL detection.
Mouse model of IRI and preparation of kidney cell
suspension
Adult C57BL/6 (B6) mice were purchased from Charles River
(Bicester, UK), and housed in a specific pathogen-free facility.
Unilateral renal artery clipping was carried out for 30 min in adult
mice under ketamine and isofluorane anesthesia. Kidneys were
harvested after 24 h, dissected, cut into 1–2 mm3 pieces, placed in
824 Kidney International (2008) 73, 816–825
o r i g i n a l a r t i c l e I Rama et al.: Hypoxia stimulates dendritic cells maturation
RPMI containing 1.6 mg ml1 collagenase I (Sigma Aldrich, Madrid,
Spain), and 200 mg ml1 DNase I (Roche Applied Science, Madrid,
Spain) for 40 min at 37 1C, washed, resuspended in RPMI/
200 mg ml1 DNase I at room temperature for 15 min, and finally
washed twice in RPMI. Following erythrocyte lysis, cells were
resuspended in RPMI/10% fetal calf serum. Final kidney cell
suspension rested for 20 min to allow sedimentation and sub-
sequently the upper two-thirds removed for flow cytometry.
Statistical analysis
Each experiment was performed at least three times and represen-
tative data are shown. Significant differences between samples were
determined by one-way analysis of variance followed by Tukey’s post
hoc test with Statistical Package for the Social Sciences (SPSS)
statistical package. Data in bar graphs are given as the mean±s.d.
A value of Po0.05 was considered significant. Differences in
cytokine expression were compared using the coefficient of variation
as a quotient of dispersion.
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